Department of Psychiatry and Behavioral Neurosciences, University of South Florida, Tampa, FL, USA; Center of Excellence for Suicide Prevention, Canandaigua VA Medical Center, Canandaigua, NY, USA.
Department of Psychiatry, McLean Hospital, Belmont, MA, USA; Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA; Department of Psychiatry, Harvard Medical School, Boston, MA, USA.
J Affect Disord. 2023 Apr 1;326:111-119. doi: 10.1016/j.jad.2023.01.082. Epub 2023 Jan 26.
BACKGROUND: Although research shows that more depressed patients respond to combined antidepressants (ADM) and psychotherapy than either alone, many patients do not respond even to combined treatment. A reliable prediction model for this could help treatment decision-making. We attempted to create such a model using machine learning methods among patients in the US Veterans Health Administration (VHA). METHODS: A 2018-2020 national sample of VHA patients beginning combined depression treatment completed self-report assessments at baseline and 3 months (n = 658). A learning model was developed using baseline self-report, administrative, and geospatial data to predict 3-month treatment response defined by reductions in the Quick Inventory of Depression Symptomatology Self-Report and/or in the Sheehan Disability Scale. The model was developed in a 70 % training sample and tested in the remaining 30 % test sample. RESULTS: 30.0 % of patients responded to treatment. The prediction model had a test sample AUC-ROC of 0.657. A strong gradient was found in probability of treatment response from 52.7 % in the highest predicted quintile to 14.4 % in the lowest predicted quintile. The most important predictors were episode characteristics (symptoms, comorbidities, history), personality/psychological resilience, recent stressors, and treatment characteristics. LIMITATIONS: Restrictions in sample definition, a low recruitment rate, and reliance on patient self-report rather than clinician assessments to determine treatment response limited the generalizability of results. CONCLUSIONS: A machine learning model could help depressed patients and providers predict likely response to combined ADM-psychotherapy. Parallel information about potential harms and costs of alternative treatments would be needed, though, to inform optimal treatment selection.
背景:尽管研究表明,与单独使用抗抑郁药(ADM)相比,联合使用 ADM 和心理疗法能使更多的抑郁症患者产生反应,但仍有许多患者即使接受联合治疗也没有反应。一个可靠的预测模型可以帮助做出治疗决策。我们尝试在美国退伍军人事务部(VHA)的患者中使用机器学习方法创建这样的模型。
方法:2018 年至 2020 年间,在美国退伍军人事务部接受联合抑郁症治疗的全国性样本患者在基线和 3 个月时(n=658)完成了自我报告评估。使用基线自我报告、行政和地理空间数据来开发学习模型,以预测 3 个月治疗反应,其定义为 Quick Inventory of Depression Symptomatology Self-Report 和/或 Sheehan Disability Scale 的减少。该模型在 70%的训练样本中进行开发,并在其余 30%的测试样本中进行测试。
结果:30.0%的患者对治疗有反应。预测模型在测试样本中的 AUC-ROC 为 0.657。从预测最高五分位数的 52.7%到预测最低五分位数的 14.4%,治疗反应的概率存在明显梯度。最重要的预测因素是发作特征(症状、合并症、病史)、人格/心理弹性、近期压力源和治疗特征。
局限性:样本定义的限制、招募率低以及依赖患者自我报告而不是临床医生评估来确定治疗反应,限制了结果的普遍性。
结论:机器学习模型可以帮助抑郁症患者和提供者预测联合使用 ADM-心理疗法的可能反应。不过,需要关于替代治疗方法的潜在危害和成本的平行信息,以告知最佳治疗选择。
Cochrane Database Syst Rev. 2012-11-14
Cochrane Database Syst Rev. 2019-5-20
JAMA Psychiatry. 2022-2-1
JAMA Psychiatry. 2021-12-1